The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
